Press Release
Moffitt Cancer Center launches first-in-nation Venture Studio for Digital Oncology - AccelerOnc Studio, and Unveils Portfolio Companies
TAMPA, Fla. — AccelerOnc Studio, the nation’s first digital oncology venture studio founded and backed by Moffitt Cancer Center, announced its initial portfolio. The studio aims to transform Moffitt’s world-class oncology research and intellectual property into companies that address critical gaps in cancer care.
“The launch of AccelerOnc Studio marks a bold step forward in our mission to contribute to the prevention and cure of cancer,” said Xavier Avat, chief business officer of Moffitt. “By transforming our research and innovations into scalable digital solutions, this venture studio expands our ability to reach patients globally and leads to a new era where technology and artificial intelligence are reshaping cancer care.”
AccelerOnc Inaugural Portfolio
BlueScrubs
- BlueScrubs is developing an artificial intelligence powered clinical decision support tool aimed at improving guideline adherence in cancer care. Oncology guidelines are frequently updated, and medical knowledge continues to expand rapidly, making it challenging for clinicians to stay current. Most cancer patients are treated in community settings, where fewer than half receive treatment based on oncology guidelines. BlueScrubs aims to bridge that gap by providing physicians with up-to-date, evidence based recommendations.
Gilmer Valdes, Ph.D., director of clinical AI at Moffitt, developed this innovative technology
and leads BlueScrubs.
ClearOnc Insights by Moffitt
- ClearOnc Insights connects patients with Moffitt oncologists through employer and payer networks. The platform enables remote expert review of medical records and treatment plans, allowing patients to access evidence-based guidance regardless of their location or case complexity.
“At AccelerOnc, we’re building a repeatable model for turning clinical insight into commercial impact,” said Kamal Jethwani, M.D., leader of AccelerOnc Studio. “Our collaboration with Moffitt brings together deep oncology expertise and venture-building experience to advance digital solutions that improve cancer care. The early momentum reflects strong demand for tools developed by oncologists for oncologists.”
AccelerOnc Studio will be featured at HLTH 2025, where leaders from health systems, pharmaceutical companies and the investment community are invited to explore collaboration opportunities.
About AccelerOnc
Founded by Moffitt Cancer Center, AccelerOnc Studio is a venture studio focused on developing new solutions for cancer care through early stage companies built on intellectual property from leading health systems. AccelerOnc supports ventures in digital health and artificial intelligence aimed at improving outcomes for patients globally. The studio connects clinical insights and entrepreneurial leadership to help shape the future of oncology innovation. For more information, please visit https://acceleronc.com/ and follow the momentum on LinkedIn.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-844-615-9372), visit MOFFITT.org, and follow the momentum on Facebook, X, Instagram and YouTube.
Read on Moffitt Cancer Center.
Media Contact:
Kim Polacek
813-504-9706